Relugolix, a form of hormone therapy for prostate cancer, has failed to significantly extend the time men with advanced disease live without acquiring resistance to castration medications, compared with standard-of-care leuprolide acetate, updated findings from the HERO trial show. While the trial (NCT03085095) had met its primary goal of increasing the proportion of patients achieving sustained testosterone reduction through 48 weeks, along with several other secondary endpoints, it now failed to demonstrate the benefits of…
You must be logged in to read/download the full post.
The post Relugolix Fails to Delay Castration Resistance in Advanced PC, Trial Shows appeared first on BioNewsFeeds.